Gene therapy, vaccines in focus as Sanofi maps out priorities

As Sanofi continues to pull back from diabetes and cardiovascular diseases, the French pharma is turning toward gene therapy and intensifying its focus on vaccines and cancer ahead of this fall’s CEO change.

The shift away from diabetes and CV began in February when Sanofi cut a dozen programs from its clinical pipeline, including two diabetes candidates and four in cardiovascular indications (see “Sanofi Drops Diabetes, CV Programs”)...